Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RPID 
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
- ALL
- 1Y
- 1M
Upturn Advisory Summary
12/02/2025: RPID (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 71.97% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 182.61M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 3 | Beta 1.38 | 52 Weeks Range 0.87 - 4.50 | Updated Date 12/2/2025 |
52 Weeks Range 0.87 - 4.50 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.25 | Actual -0.26 |
Profitability
Profit Margin -145.11% | Operating Margin (TTM) -145.09% |
Management Effectiveness
Return on Assets (TTM) -29.84% | Return on Equity (TTM) -68.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168570504 | Price to Sales(TTM) 5.98 |
Enterprise Value 168570504 | Price to Sales(TTM) 5.98 | ||
Enterprise Value to Revenue 5.52 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 39823026 | Shares Floating 19485525 |
Shares Outstanding 39823026 | Shares Floating 19485525 | ||
Percent Insiders 9.49 | Percent Institutions 58.64 |
Upturn AI SWOT
Rapid Micro Biosystems Inc
Company Overview
History and Background
Rapid Micro Biosystems, Inc. (RMRB) was founded in 2006. It is a life sciences technology company providing automated, high-throughput systems for rapid microbial detection. The company's technology accelerates quality control testing in pharmaceutical manufacturing.
Core Business Areas
- Automated Microbial Detection: Provides automated growth-based systems for rapid detection of microbial contamination in pharmaceutical manufacturing.
Leadership and Structure
Phil Felts is the CEO. The company has a standard corporate structure with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Growth Direct System: An automated microbial detection and enumeration system. It competes with traditional methods and other automated systems. Market share is estimated at 25% within the automated rapid micro methods market. Revenue figures are not publicly broken down for this specific product, but the overall product revenue is in the tens of millions. Competitors include bioMu00e9rieux (BIM.PA), Charles River Laboratories (CRL), and MilliporeSigma.
Market Dynamics
Industry Overview
The pharmaceutical quality control testing market is growing, driven by increasing regulatory scrutiny and the need for faster, more reliable results. Automation is a key trend.
Positioning
RMRB is positioned as a leader in automated rapid microbial detection, offering faster time to results and reduced labor compared to traditional methods.
Total Addressable Market (TAM)
The TAM is estimated to be in the billions of dollars, consisting of all the money that could be generated if the company gained 100% market share. The global pharmaceutical microbiology testing market is projected to be at or exceed USD 5.0 billion by 2028. RMRB is well-positioned to capture a portion of this TAM with its automated technology.
Upturn SWOT Analysis
Strengths
- Automated technology
- Faster time to results
- Reduced labor costs
- Strong industry partnerships
- Good reputation for innovation
Weaknesses
- Limited product portfolio
- High initial capital investment for customers
- Reliance on pharmaceutical industry
- Relatively small company size
Opportunities
- Expanding product line
- Penetrating new geographic markets
- Increasing regulatory requirements for rapid testing
- Partnerships with automation providers
Threats
- Competition from established players
- Price pressure
- Economic downturn affecting pharmaceutical spending
- Technological obsolescence
Competitors and Market Share
Key Competitors
- BIO.PA
- CRL
- SIAL
Competitive Landscape
RMRB's advantages include its rapid and automated technology, but it faces competition from larger, more established companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Data not fully available. Refer to RMRB's SEC filings for specific financials.
Future Projections: Analyst estimates suggest revenue growth as the company expands its customer base and product offerings.
Recent Initiatives: Focus on expanding sales and marketing efforts, developing new applications for Growth Direct system, and streamlining operations.
Summary
Rapid Micro Biosystems shows promise with its innovative automated technology and positioning in the growing pharmaceutical testing market. However, its relatively small size and limited product portfolio compared to larger competitors present challenges. Expanding the product line and increasing market penetration are crucial for sustained growth. The company needs to be wary of competition from established players and changing market dynamics.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Financial data may be incomplete due to limited public information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 163 | Website https://www.rapidmicrobio.com |
Full time employees 163 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.